** Shares of Imugene Ltd IMU.AX rise as much as 4.8% to
A$0.110, their highest level since June 5
** Immune-oncology co announces collaboration with
biopharmaceutical co RenovoRx Inc RNXT.O
** Says collaboration will explore trans-arterial delivery
of Imugene's CF33 oncolytic virus therapy
** Says collaboration will help facilitate treatment of
difficult-to-access tumours
** Shares on track for their second session of gain
** Shares down 27.6% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))